⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Table 3 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Christopher T. Chen Vishesh Khanna Shivaani Kummar Raghad M. Abdul-Karim David Sommerhalder Anthony W. Tolcher Naoto T. Ueno S. Lindsey Davis Douglas W. Orr Erika Hamilton Manish R. Patel Alexander I. Spira Shekeab Jauhari Vaia Florou Maureen Duff Rongda Xu Jian Wang Shravani Barkund Haiying Zhou Aleksandr Pankov Wayne Kong Nadine S. Jahchan Erica L. Jackson Jessica D. Sun Melissa R. Junttila Pratik S. Multani Anneleen Daemen Edna Chow Maneval Pamela N. Münster

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Antitumor activity at the RP2D

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db643587526141 https://doi.org/10.1158/2767-9764.27015359.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 3 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
2Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
3Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
4Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
5Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024

Figure 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
Data from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors2024